The global non-insulin therapies for diabetes market is poised for substantial growth over the next decade, reflecting the rising prevalence of diabetes worldwide and the increasing focus on innovative treatment options beyond insulin. In 2023, the market was valued at approximately US$ 31.8 billion, underscoring the significant demand for alternative therapies that offer better patient adherence, improved glycemic control, and reduced risk of side effects commonly associated with insulin treatments. With advancements in pharmacology and biotherapeutics, non-insulin therapies are gaining traction among healthcare providers and patients, creating a robust growth environment for key industry players.
Access key findings and insights from our Report in this sample – https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86328
Market Size and Growth
The non-insulin therapies market is projected to experience a steady growth trajectory, expanding at a compound annual growth rate (CAGR) of 5.8% from 2024 to 2034, and reaching an estimated US$ 58.6 billion by the end of 2034. This growth is primarily driven by factors such as the increasing prevalence of type 2 diabetes, rising awareness regarding diabetes management, and the continuous launch of novel therapies that target different mechanisms of blood glucose regulation. Additionally, the aging global population and the rising incidence of obesity are contributing significantly to the expanding patient pool for non-insulin therapies. Pharmaceutical companies are also investing heavily in research and development, further fueling the market’s growth prospects over the next decade.
Market Segmentation
The market for non-insulin therapies is broadly segmented based on drug type, route of administration, and end-user demographics. Key drug types include oral hypoglycemics, GLP-1 receptor agonists, DPP-4 inhibitors, SGLT2 inhibitors, and combination therapies, each addressing different aspects of glycemic control. Oral medications continue to dominate due to ease of administration and patient preference, while injectable non-insulin therapies are witnessing growing adoption because of their efficacy and potential for weight management benefits. End-users range from hospitals and specialty clinics to homecare settings, reflecting a diverse demand ecosystem and highlighting the need for patient-centric therapeutic solutions.
Regional Analysis
Geographically, North America remains a significant market for non-insulin diabetes therapies, supported by high healthcare expenditure, well-established healthcare infrastructure, and early adoption of novel treatments. Europe follows closely, driven by supportive healthcare policies and increasing patient awareness. Meanwhile, the Asia-Pacific region is expected to emerge as a high-growth market due to rising diabetes prevalence, expanding healthcare access, and increasing adoption of advanced therapies in countries such as China, India, and Japan. Latin America and the Middle East & Africa, while smaller in current market share, are witnessing gradual growth due to improving healthcare infrastructure and growing public health initiatives.
Competitive Landscape
The non-insulin therapies market is characterized by the presence of several major global pharmaceutical companies investing in product innovation and strategic partnerships. Key players include GSK plc, Eli Lilly and Company, Sumitomo Pharma, Intarcia Therapeutics, Servier Laboratories, Pfizer Inc., Merck & Co., Inc., Dong-A Pharmaceutical Co., Ltd., Luye Pharma Group, and Eurofarma Laboratories SA. These companies are actively engaging in strategic mergers, acquisitions, and product launches to strengthen their market positions and expand global reach.
About Transparency Market Research
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Contact:
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Comments (0)